✨ Medicines Consent Notices




NEW ZEALAND GAZETTE

No. 114

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Ketoprofen 100 mg, 200 mg capsules Elan Pharma Limited, Athlone, Ireland Kapren SR
Theophylline (anhydrous) 250 mg, 375 mg slow release capsule Byk Nederland BV, Swanenberg, The Netherlands Euphylong
This product is not substitutable with other Theophylline medicines
Methyl salicylate 20% w/w, Menthol 0.75% w/w, Camphor 1.0% w/w, Eucalyptus Oil 0.5% w/w topical cream Milpharma Pty Limited, Brookvale, New South Wales, Australia Dencorub
Indomethacin 1% w/w topical solution Luitpold-Pharma GmbH, Munchen, Germany Elmetacin
Pine Tar 2.3% topical solution Hamilton Laboratories, Adelaide, South Australia Dermatar
4-hydroxyandrostenedione 250 mg powder for reconstitution for injection Ciba-Geigy Limited, Basle, Switzerland Lentaron
Haemophilus influenzae type b conjugate vaccine containing H.influenzae type b polysaccharide 15.0 mcg and N.meningitidis group B (strain B11) outer membrane protein complex 225.0 mcg per dose. lyophilised powder with aluminium hydroxide diluent for injection Merck & Co. Inc., West Point, Pennsylvania, United States of America Pedvax HIB
Estradiol 50 mcg norethisterone 0.25 mg transdermal therapeutic system (patches) Ciba-Geigy Limited, Basle, Switzerland Estragest TTS
Estradiol 50 mcg estradiol 50 mcg/0.25 mg norethisterone transdermal therapeutic system (patches) Ciba-Geigy Limited, Basle, Switzerland Estracomb TTS

Dated this 16th day of July 1992.

C. LOVEACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day of June 1991.

go6594

Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Nifedipine 30 mg, 60 mg, 90 mg controlled release tablet Pfizer Pharmaceutical Inc., Barceloneta, Puerto Rico and Alza Corporation, Vacaville, California, United States of America Adalat Oros
Etodolac 400 mg, 600 mg slow release tablets Wyeth S.p.a., Aprilia (Latina), Italy Lodine
Etodolac 200 mg, 300 mg tablets John Wyeth & Brother Limited, Taplow, Maidenhead, Berkshire, United Kingdom Lodine
Etodolac 300 mg capsules John Wyeth & Brother Limited, Taplow, Maidenhead, Berkshire, United Kingdom Lodine
Isradipine 100 ug/ml solution for intravenous administration Sandoz Pharma Limited, Basle, Switzerland Dynacirc IV

Dated this 16th day of July 1992.

C. LOVEACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day of July 1992.

go6595



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1992, No 114


NZLII PDF NZ Gazette 1992, No 114





✨ LLM interpretation of page content

πŸ₯ Consent to Distribution of New Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
16 July 1992
Medicines, Distribution, Consent, Schedule
  • C. Loveace, Director-General of Health

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
16 July 1992
Medicines, Distribution, Consent, Schedule, Changes
  • C. Loveace, Director-General of Health